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Bradykinin causes selective efferent arteriolar dilation during
angiotensin I converting enzyme inhibition
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Bradykinin causes selective efferent arteriolar dilation during angioten-
sin I converting enzyme inhibition. We studied the effects of interruption
of the renin-angiotensin system (RAS) in rats that were volume depleted
by water deprivation for 48 hours (AWD) with/without furosemide
(AWD + F), a condition known to activate RAS. Following baseline
micropuncture, AWD rats (N = 6) were treated with a specific
angiotensin II type 1 receptor antagonist (AuRA; 4 mg/kg body wt
bolus i.v. and then continuous infusion) and glomerular hemodynamics
compared to those obtained during angiotensin I converting enzyme
inhibitor treatment (ACEI; 24 mg/kg bolus i.v. and then continuous
infusion). Systemic blood pressure decreased equally following AHRA
and ACEI. Single nephron glomerular filtration rate (SNGFR) increased
from baseline following AuRA (24 nI/mm vs. 30, P < 0.025). While a
decrease in efferent arteriolar resistance (RE) reduced glomerular
capillary pressure (P0; 67 mm Hg vs. 60, P < 0.05), this change in RE
together with decrease in afferent arteriolar resistance (RA), enhanced
glomerular plasma flow rate (QA; 80 nI/mm vs. Ill). Antagonizing
angiotensin II receptor increased QA which, together with the tendency
to increase glomerular capillary ultrafiltration coeffIcient, K, served to
improve glomerular filtration. By contrast, although inhibition of the
angiotensin I converting enzyme caused greater vasodilatation, no
increase in SNGFR occurred. The lack of response in filtration after
ACEI was due to a further fall in P0 to 52 mm Hg (P < 0.01 vs.
AuRA), reflecting profound reduction in R. Since ACE! but not
AuRA potentiates bradykinin activity we examined effects of a specific
bradykinin antagonist (Hoe). In a separate group of AWD+F rats (N =
6), ACE! again caused significant renal vasodilatation without affecting
filtration rate. The ACEI-induced decrease in resistances was substan-
tially antagonized by inhibition of bradykinin activity. Thus, Hoe
significantly increased RE, effectively raising GC by9mm Hg (P < 0.05
vs. ACE!) and thus secondarily effecting increased filtration (SNGFR
22 nI/mm vs. 28, P < 0.05, ACE! vs. Hoe). In contrast to these results
with ACE!, treatment with AuRA significantly increased GFR, and
addition of bradykinin antagonist (N = 4) did not cause further increase
infiltration. Thus, in conditions where high P0 is crucial in maintaining
GFR, activation of bradykinin by ACE! can compromise GFR second-
ary to bradykinin's selective vasodilatory action on the efferent arte-
riole.
Angiotensin II (Ang II) is now known to act at several sites
within the renal microcirculation [1—6]. Angiotensin I convert-
ing enzyme inhibitor (ACE!) has been used as a primary tool to
determine the sites of endogenous Ang II actions. In this
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regard, while ACE! decreases resistances of both afferent and
efferent arterioles, its more profound effect on the efferent
arteriolar tone is reflected by reduced efferent arteriolar resis-
tance or decreased filtration fraction. Moreover, clinically,
efforts to vasodilate and improve organ blood flow with ACE!
can cause deterioration in GFR. In addition, RAS has been
postulated to be linked to other vasoactive substances, notably
bradykinin, which may account for part of ACEI-induced
vasodilatation [7—12]. Assessment of the specific effects of
endogenous Ang II on the renal circulation has been limited by
this uncertain non-specific action of ACE!, and also by the
partial agonist effects of previously available Ang II analogues.
Recently, the availability of both a specific nonpeptide Ang I!
receptor antagonist (A!IRA) which lacks agonist effects [13,
14], and a specific bradykinin receptor antagonist [15] has
circumvented these concerns. By comparing the effects of
AuRA versus ACE! in a model with enhanced Ang I!, we
ascertained the specific actions attributable to Ang I! per se and
those attributable to Ang Il-unrelated ACE! effects. Further,
we explored the role of bradykinin, which may underlie the
unique intrarenal effects of ACE! observed in a variety of
settings.
Methods
Experiments were done in adult male Munich-Wistar rats. All
animals were deprived of water for 48 hours (acute water
deprivation, AWD), a model characterized by hypoperfusion,
hypofiltration and activated RAS [6, 16, 17]. Renal function was
then assessed as described in detail below. AWD decreased the
body weight, on average, by 15%.
Group I AWD treated with ACE! (N = 6)
Rats were prepared for micropuncture as previously de-
scribed [6, 16, 17]. Briefly, under mactin anesthesia (70 mg/kg
body wt i.p.; BYK, Konstanz, Germany), tracheotomy was
performed, and indwelling polyethylene catheters were inserted
into the femoral artery and vein and the jugular vein for blood
sampling, monitoring of systemic blood pressure, and infusion
of inulin and plasma, as previously described [6, 16, 17].
Determinations of SNGFR, hydraulic pressures in glomerular
capillaries (PGc), proximal tubules, and efferent arterioles were
made. Femoral arterial (CA) and efferent arteriolar (CE) plasma
protein concentrations were also obtained, permitting calcula-
tion of glomerular plasma flow rate (QA) and ultrafiltration
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coefficient (Kf), as well as resistances of afferent (RA) and
efferent (RE) arterioles. Colloid osmotic pressures of plasma
entering and leaving the glomerular capillaries were estimated
from CA and CE using derivations of Deen eta! [18, 19]. Details
of the analytical procedure for inulin in plasma and nanoliter
tubule fluid samples, and that for CA and CE are described
elsewhere [18, 19]. After baseline measurements and collec-
tions, each rat was treated with ACE! (enalapril, 0.24 mg/kg i.v.
bolus, then 0.24 mg/hr continuous i.v. infusion). After 60
minutes, micropuncture measurements were repeated.
Group II AWD treated with AuRA and ACE! (N =6)
Rats were prepared as in Group ! except that, after baseline
measurements, A!IRA (4 mg/kg body wt i.v. as bolus and then
as continuous infusion, L 158,809, Merck, Sharp & Dohme), a
specific type I angiotensin receptor !I antagonist, was started.
This antagonist shows high affinity and selectivity for the type I
receptor with no agonist activity [13, 14, 20]. Rena! micropunc-
ture measurements were performed one hour after AuRA was
started. AuRA was then discontinued and ACEI was infused as
in Group ! with repeat micropuncture measurements after one
hour. These doses for AuRA and ACE! are based on the
minimum depressor doses established in our previous study in
the remnant kidney hypertension mode! [21]. Since the AuRA
has half life exceeding six hours in the rat [14] and effects in the
ACEI period may in part reflect alterations of the RAS after
receptor inhibition, we studied separate groups of animals
treated with either ACE! or AI!RA.
Groups lilA and B, AWD + furosemide, treated with ACE!
(N = 6) or AuRA (N = 6)
To confirm differences in renal function between ACE!
versus A!!RA under conditions with extreme stimulation of the
RAS, we studied animals that received furosemide in addition
to water deprivation. Furosemide (2.5 mg/kg body wt i.p.) was
administered at the start of water deprivation and again the next
day which was at least 24 hours prior to micropuncture/
clearance studies to avoid confounding effects of furosemide
activation of tubuloglomerular feedback. Following surgical
preparation, baseline clearance studies were obtained as previ-
ously described [6, 16, 171. The animals were then treated with
either ACE! (Group !IIA, N = 6) or AI!RA (Group II!B, N =
6), as described above. Measurements were repeated 60 min-
utes later.
Group IVA, B, and C; AWD + furosemide rats, treated with:
ACE! + bradykinin receptor antagonist, Hoe (A, N =9), or
AuRA + Hoe (B, N = 4) or Hoe (C, N = 6)
These animals were prepared as Group !I!A (baseline, then
ACE! or A!IRA) but, in addition, a third period of study was
added. Thus, during ACE! treatment renal hemodynamic stud-
ies were performed, and then a newly developed bradykinin
antagonist was added (0.1 mg/kg body wt i.v. bolus and s.c.,
Hoe-l40, Hoechst, Frankfurt, Germany). Micropuncture mea-
surements were then performed. The bradykinin antagonist has
previously been shown to be highly specific in vivo, completely
preventing systemic hypotension in response to exogenous
bradykinin one hour after administration of the antagonist.
Even two hours after bradykinin antagonist, exogenous brady-
kinin caused only minima! hypotension (—5% decrease in blood
pressure) [15]. Group !VB were rats treated identically except
that AuRA, instead of ACE!, was given. Renal function was
assessed at the same time points as in Group IVA animals.
Group IVC rats were treated identically, except that no ACE!
or AIIRA was given, only Hoe. The same dose of Hoe was
administered before measurement of renal clearances at one
hour.
To assess a potential role for prostaglandins in the effects of
ACE! versus A!!RA, a separate group of AWD rats was
pretreated with indomethacin, 2 mg/kg body wt/hr i.v. Follow-
ing micropuncture/clearance studies, the animals received ei-
ther ACE! (N = 4) or AuRA (N = 4) as above, and renal
studies were repeated.
Statistics
Results are given as mean SE. Data were analyzed by
ANOVA, followed by post hoc paired or unpaired Student's
t-test, as appropriate. Results were considered statistically
significant at P < 0.05.
Results
Group I, AWD treated with ACEI
Whole kidney GFR, SNGFR, and QA (0.46 0.07 mI/mm,
16.2 1.9 nLlmin, and 53 6 nllmin, respectively) were
characteristic of the hypoperfusionlhypofi!tration pattern of
renal hemodynamics and distinct from normal euvolemic rats
[6, 16, 17]. These parameters reflect higher than normal afferent
and efferent arteriolar resistances (0.402 0.044 mm Hg mini
nl and 0.543 0.085, respectively). !nhibition of angiotensin I
converting enzyme activity decreased MAP from 107 6 mm
Hg to 94 5, and caused renal dilation. Thus, QA values
increased to 102 24 nI/mm, due to a decrease in arteriolar
resistances, particularly of the efferent arteriole (from 0.543
0.085 mm Hg mm/n! to 0.235 0.048, P < 0.025). The fall in
RE was apparent in the profound decrease in the intrag!omer-
ular pressure; P- fell from the higher than typical euvolemic
value of 65 2 mm Hg to 49 1 (P < 0.005). As expected,
inhibition of angiotensin !I activity caused an increase in the
value of Kf [1.020 0.240 n1J(min mm Hg) vs. 2.700 0.600,
P < 0.025]. The cumulative effect of these changes was the lack
of consistent improvement in filtration (GFR 0.46 0.07 vs.
0.54 0.06, P = NS). !n the next set of experiments, the
mechanism of angiotensin I!'s actions on the glomerular micro-
circulation was explored by interrupting the RAS at different
points in its synthetic pathway.
Group II AWD treated with AuRA and ACE!
Group !I rats were prepared identically to Group I and again
showed the typical renal hypoperfusion of AWD. These data
are shown in Table 1 and Figure 1. !n contrast to Group !
ACEI-treated rats, both GFR (P < 0.05) and SNGFR (P <
0.025) increased significantly with A!IRA. Evaluation of indi-
vidual parameters that affect filtration revealed vasodilatation,
particularly due to a fall in efferent arteriolar resistance (P <
0.05). Of note, while GC fell from 67 3 mm Hg to 60 2 (P
<0.05), this decrease was markedly less than that observed in
Group ! ACE!-treated rats, where average P decreased by 16
mm Hg. Whether inhibition of converting enzyme in the setting
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Table 1. Systemic and renal microcirculatory parameters in AWD rats in response to inhibition of the renin-angiotensin system
MAP
mm Hg
GFR
mi/mm
SNGFR
PGC
mm Hg
RA RE Kfnl/(min mm
Hg)ni/mm mm Hg mm/ni
Baseline 95 2 0.46 0.07 25,2 2.5 82 7 67 3 0.170 0.015 0.333 0.042 1.322 0.368
AuRA 88 2 0.59 0.05a 30.2 2.3a Ill 21 60 2 0.143 0.023 0.240 0.037a 1.968 0.311
ACE! 89 2 0.41 0.04" 21.5 1.1" 134 19 52 l 0.169 0.016 0.159 0.032a 2.188 0.381
Abbreviations are: AWD, acute water deprivation; MAP, mean arterial pressure; GFR, whole kidney glomerular filtration rate; SNGFR, single
nephron GFR; QA' initial glomerular plasma flow rate; P0,, glomerular capillary hydraulic pressure; RA, afferent arteriolar resistance; RE, efferent
arteriolar resistance; Kf, glomerular capillary ultrafiltration coefficient.
a p < 0.05 vs. baseline
b P < 0.05 vs. AuRA (specific P values in the text)
E
E
(.)
of previous antagonism of Ang II receptor had an additional
independent effect on filtration was then examined.
ACEI following AuRA caused a profound fall in the rate of
filtration: GFR and SNGFR fell even below baseline (Table 1).
Of note, the profound hypofiltration occurred in the face of
renal dilatation. QA increased further to 134 19 nllmin (P <
0.025 vs. baseline), largely reflecting a marked decrease in the
efferent arteriolar resistance. As in Group I, this was associated
with a precipitous decrease in P0w, which was on average 15
mm Hg lower than baseline value.
Groups lilA and B, AWD + furosemide, treated with ACEI
or AuRA
Due to the potential persisting actions of the long lasting
AuRA, separate groups of animals were treated with ACE!
(Group lilA) or AuRA (Group IIIB). To confirm differences in
renal microcirculatory responses to ACE! versus AuRA under
conditions with extreme stimulation of the RAS, these animals
received furosemide in addition to AWD. Group III rats were
more profoundly dehydrated than Groups I and II as evidenced
by higher hematocrit (60 1% vs. 52 1 and 51 1,
respectively, for Group III vs. Group I and II, P < 0.0005).
MAP decreased from baseline in both Groups lilA and I!IB
with treatment: 93 6 mm Hg to 87 5 (P <0.025), and 93
6 mm Hg to 83 3 (P < 0.05), respectively (Fig. 2). Similar to
Groups I and II, ACE! did not affect GFR (0.61 0.04 mI/mm
vs. 0.61 0.05). In contrast to ACEI, inhibition of angiotensin
II with receptor antagonist resulted in marked improvement in
GFR which, on average, increased from 0.51 0.07 mLtmin to
0.72 0.09 (P < 0.01).
Fig. 1. Individual glomerular capillary
pressure (P) values in Group II A WD rats
during baseline and following angiotensin II
receptor antagonist (AuRA) and angiotensin I
converting enzyme inhibitor (ACE!) showing
markedly greater fall in Pc with ACE!.
Group IVA, B, and C; AWD + furosemide rats, treated with:
ACE! + bradykinin receptor antagonist, Hoe (A, N 9), or
AuRA + Hoe (B, N = 4) or Hoe (C, N = 6)
To further explore the mechanisms underlying these differing
effects on the rate of glomerular filtration, we studied the
potential contribution of bradykinin, as ACEI, unlike AuRA,
acts as a kininase inhibitor. For this purpose, we evaluated the
renal microcirculation in response to a specific bradykinin
receptor antagonist. ACE! decreased MAP (98 3 mm Hg to 90
2) and increased renal perfusion without improving hypofil-
tration, GFR 0.50 0.08 mllmin versus 0.58 0.08, SNGFR 21
2 nL/min versus 22 2. The individual parameters are shown
in Figure 3, again emphasizing the marked decrease in P6C
following ACE! (63 4 mm Hg vs. 53 3, P < 0.005). The
contribution of bradykinin was evaluated in the third period.
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Fig. 2. Mean arterial pressure (MAP) and glomerular filtration rate(GFR) in AWD rats treated with furosemide then either ACE! orAIIRA.
MAP decreased similarly in both ACE!, Group lilA (Lx) and AuRA,
Group IHB (A). By contrast, GFR, was unchanged with ACEI (0) and
increased dramatically with AuRA (•).
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Fig. 3. Summary of effects ofACEI and bradykinin antagonist (Hoe) in
AWD + furosemide Group IVA rats. The decrease in glomerular
capillary pressure (P0) with ACEI was restored with Hoe, primarily
reflecting elevation in efferent arteriolar resistance, R5.
MAP was unchanged from that during ACE! treatment. Filtra-
tion increased significantly; GFR rose to 0.71 0.10 mI/mm (P
<0.005 vs. ACE!), and SNGFR increased to 28 3 nI/mm (P
<0.05 vs. ACE!). This improvement in filtration was due to an
increase in glomerular pressure which returned toward the
baseline level (62 6 mm Hg, P < 0.05 ACE! vs. Hoe),
reflecting return of efferent arteriolar resistance to baseline
levels, 0.3 12 0.050 mm Hg min/nl. This increase in efferent
arteriolar resistance offset the tendency for the afferent arterio-
lar resistance to decrease, such that glomerular plasma flow rate
remained unchanged, and thus was not a contributor to the
increase in GFR. The value for Kf was not affected by the
bradykinin antagonist [1.735 0.320 nll(min mm Hg) vs. 1.465
0.472, ACE! vs. Hoe, respectively]. In Group IVB, AWD +
furosemide animals treated with AuRA then Hoe, blood pres-
sure tended to decrease, 100 2 mm Hg at baseline versus 94
2 with AuRA, and 91 I with Hoe. Baseline GFR was 0.57
0.09 mllmin, and increased to 0.84 0.14 (P < 0.05) with
AuRA, similar to the values observed in identically prepared
animals in Group huB. However, in contrast to the pattern
observed in ACEI-treated animals (Group IVA), bradykinin
antagonist did not cause further increase in GFR (0.65 0.15
mI/mm). In Group IVC, AWD + furosemide animals treated
with the bradykinin antagonist alone, GFR was 0.81 0.10
mllmin at baseline, with no significant change after bradykinin
antagonist, 0.89 0.19 mI/mm.
Separate AWD rats were treated with either ACE! or AIIRA
after prostaglandin inhibition with indomethacin. In spite of
animal variability, different effects of ACEI versus AuRA
persisted: SNGFR showed —20% increase over baseline after
ACE! while AuRA caused a 100% increase (P < 0.05), QA
increased —70% versus ---140%, and RA decreased —30%
versus —60% (P < 0.05), respectively. These findings are taken
to suggest that prostaglandins are not the major intermediary
mechanism for the divergence between vasodilatation and
perfusion seen after ACE! versus AIIRA.
Discussion
The renin-angiotensin system is important in regulating Va-
somotor tone in the systemic and organ vasculatures. Interrup-
tion of the RAS to decrease vasoconstriction is often a thera-
peutic goal, but is associated with variable effects on GFR [6,
17, 22—31]. We therefore studied the AWD rat, a model char-
acterized by hypoperfusion and hypofiltration with activation of
the RAS. Antagonizing Ang II actions by inhibition of convert-
ing enzyme vasodilated the systemic and renal circulations;
systemic blood pressure decreased and renal plasma flow
increased, however, there was little change in GFR. Analysis of
the microcirculatory hemodynamics revealed that arteriolar
resistances decreased, particularly in the efferent arteriole,
which contributed to the increase in QA. However, the efferent
arteriolar dilatation also caused a profound fall in GC (by 16
mm Hg), which offset the effects of increases in QA and Kf, and
resulted in no net change in SNGFR. These findings are in
accord with reports that inhibition of RAS can increase, de-
crease, or leave unchanged the rate of filtration, and emphasize
that the net effect on GFR depends upon the balance of Ang II's
effects on RA, RE and Kf [6, 16, 17, 25]. Thus, enhancement or
preservation of GFR after interruption of RAS represents
greater contribution of increased QA and K versus reduced GC
[25]. By contrast, in more severe hemodynamic decompensa-
tion, glomerular filtration may be critically dependent on height-
ened RAS which promotes efferent arteriolar maintenance of
Gc and GFR. Removal of this critical compensation then leads
to a fall in GFR [17]. This notion is supported by observations
that decreased GFR and azotemia develop in patients on ACE!
with superimposed circulatory stress such as blood loss, addi-
tion of diuretics or other fluid loss, which overwhelms already
maximal compensation by RAS [23, 24, 26—29, 32]. A recent
study emphasizes the importance of treatment with ACE! as a
cause for hypofiltration. Thus ACE! has been found to be the
second most common cause of treatment-related fall in GFR
[33]. It should be emphasized that hypofiltration occurs even in
the absence of profound systemic hypotension [23, 32]. Fur-
ther, for a similar decrease in systemic blood pressure, hypo-
filtration occurs more frequently when RAS is inhibited com-
pared with systemic vasodilatation achieved with maneuvers
not involving RAS inhibition. These findings then implicate
renal, rather than systemic, changes which are responsible for
decreasing filtration.
Angiotensin II per se or Ang II independent mechanisms may
regulate the glomerular hemodynamic compensation. To exam-
ine this issue, we studied the effects of a specific angiotensin II
type I receptor antagonist (AIIRA). The angiotensin type I
receptor is one of two angiotensin receptor types identified in
humans, and is the subtype that mediates cardiovascular ac-
tions of Ang II [34]. The renal distribution of the mRNA of this
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receptor was examined in our recent in situ hybridization
studies. No signal was detected in interlobular arteries while
this signal was prominent in vessels regulating blood flow and
filtration, including both afferent and efferent arterioles and the
mesangium [35]. In contrast to ACE!, the present study shows
that antagonizing type I angiotensin I! vascular receptor caused
renal vasodilatation, which was accompanied by a striking
increase in filtration (Table 1, Figs. 1 and 2). This difference was
apparent between periods within an animal and also between
groups. While the magnitude of decrease in systemic blood
pressure and increase in QA were similar, antagonism of angio-
tensin II with a receptor antagonist resulted in lesser reduction
in efferent arteriolar tone than inhibition of ACE (Table 1, Fig.
3). This is reflected by the changes in GC• Thus, although
systemic blood pressures was decreased to the same degree by
both ACE! and AuRA, ACE! caused GC to fall by 16 mm Hg,
compared with 7 mm Hg fall following AuRA.
Differences in the microcirculatory hemodynamic changes
after interrupting the RASat these different sites of action, that
is, at the interaction of ligand and type I receptor versus
inhibition of conversion of angiotensin I to angiotensin I!,
suggest that other Ang!! effects or non-Ang I! actions contrib-
ute, at least in part, to the dyssynchrony between renal vaso-
dilatation and filtration following ACE!. In this regard, circu-
lating levels of angiotensin I! modulate expression of the genes
of the RAS, including renin, angiotensinogen and ACE [36].
Since circulating Ang I! levels are higher after A!IRA than
ACE! treatment [37], this higher level of unbound angiotensin I!
can interact with other vasoactive substances, or bind with type
I! receptor or other angiotensin binding proteins. The conse-
quences of ligand binding at these sites is not yet known. The
possibility of additional, non-Ang II effects (such as interaction
with vasodilators) is of interest in view of the previous obser-
vation that rats with renal hypoperfusion, because of congestive
heart failure and AWD, developed a paradoxical fall in efferent
arteriolar tone in response to superimposed reduction in renal
perfusion pressure [17]. In this setting, the expected renal
vasodilatation is postulated to reflect attenuation of Ang I!
actions. However, the observations suggest that the failure to
increase or even decrease GFR during such renal vasodilatation
is not simply attenuation of Ang II effects, rather it is an active
vasodilatation.
Some vasodilators are associated with RAS, including bra-
dykinin, endothelium-derived relaxing factor and prostaglan-
dins, although our data suggest that the latter do not have a
major role in this regard. Of note, angiotensin I converting
enzyme inhibitors inactivate kininase II, a kinin-degrading
enzyme which would result in accumulation of bradykinin.
Bradykinin's contribution to ACE!-induced vasodilatation has
been controversial [8—12, 38—40]. There is accumulating evi-
dence that kinins play an important role in regulating renal
function, including recent evidence that kinins can be formed in
the renal circulation. This is of particular relevance since among
isolated rabbit interlobular, efferent and afferent arteriolar
preparations, bradykinin caused marked vasodilatation only in
the efferent arteriole [41]. We therefore investigated whether
bradykinin plays a role in the ACE!-induced vasodilatation, and
in particular whether the dramatic decrease in efferent arteriolar
resistance is related to the enhanced bradykinin activity. Our
studies in animals treated with ACE! clearly show that antag-
onizing bradykinin opposed the decrease in efferent arteriolar
resistance effected by converting enzyme inhibition (Fig. 3).
This in turn caused an elevation in glomerular pressure which
was pivotal in increasing GFR. In contrast, animals treated with
A!IRA, increased GFR but, unlike ACE!, addition of bradyki-
nm antagonist did not result in further increases in glomerular
filtration.
Interruption of the RAS by ACE! is now used in many
circumstances to lower blood pressure, to effect afterload
reduction, decrease proteinuria and also to forestall chronic
deterioration in renal function. While vasodilatation and renal
sparing is a desirable therapeutic end point in the kidney, a
decrease in vascular resistance can cause not only renal vaso-
dilatation but also may decrease glomerular capillary pressure,
and therefore remove an important compensatory mechanism
to maintain GFR. These data show that renal vasodilatation
following inhibition of angiotensin I converting enzyme is at
least in part related to bradykinin. These studies further indi-
cate that in conditions where high GC is crucial in maintaining
GFR, activation of bradykinin by ACEI can precipitate severe
compromise in GFR, and that this untoward effect can be
largely avoided with a more specific vasodilator for antagonism
of angiotensin II effects.
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